TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer Meeting Abstract
| Authors: | Forero-Torres, A.; Lin, N. U.; Liu, M. C.; Rugo, H. S.; Puhalla, S.; Nanda, R.; Mayer, I. A.; Storniolo, A. M.; Traina, T. A.; Hayes, D. F.; Rimawi, M. F.; Goetz, M. P.; Esteva, F. J.; Irvin, W. J.; Wolff, A. C.; on behalf of the Translational Breast Cancer Research Consortium |
| Abstract Title: | TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880304553 |
| DOI: | 10.1200/jco.2011.29.15_suppl.tps128 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS128 -- Source: Wos |
